To further demonstrate the robustness of our results, we performed the sensitivity analysis in the diabetic and prediabetic populations with prediabetes (sensitivity-1), with diabetes with hypoglycaemic drugs or insulin (sensitivity-2), with CVD (sensitivity-3), with after excluding participants who died within the first 2 years of follow-up (sensitivity-4) and. This evidence concerns the gene INS and diabetes mellitus.